Cargando…
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368716/ https://www.ncbi.nlm.nih.gov/pubmed/30736842 http://dx.doi.org/10.1186/s13045-019-0703-z |
_version_ | 1783394044082126848 |
---|---|
author | Liu, Delong Zhao, Juanjuan Song, Yongping Luo, Xiaofeng Yang, Ting |
author_facet | Liu, Delong Zhao, Juanjuan Song, Yongping Luo, Xiaofeng Yang, Ting |
author_sort | Liu, Delong |
collection | PubMed |
description | The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made. In addition to the tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, immunotherapeutic agents, blinatumomab, inotuzumab ozogamicin (INO), and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being incorporated into induction chemotherapy regimens and combined with TKIs for ALL therapy. A novel low-intensity regimen, miniHCVD-INO-blinatumomab, appears to be less toxic and more effective than conventional intensive chemotherapy regimens. This review summarized new therapeutic researches of ALL and updated latest progress in clinical trials on bispecific antibodies, antibody-drug conjugates, and new regimens incorporating these novel antibodies. |
format | Online Article Text |
id | pubmed-6368716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63687162019-02-15 Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia Liu, Delong Zhao, Juanjuan Song, Yongping Luo, Xiaofeng Yang, Ting J Hematol Oncol Review The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made. In addition to the tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, immunotherapeutic agents, blinatumomab, inotuzumab ozogamicin (INO), and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being incorporated into induction chemotherapy regimens and combined with TKIs for ALL therapy. A novel low-intensity regimen, miniHCVD-INO-blinatumomab, appears to be less toxic and more effective than conventional intensive chemotherapy regimens. This review summarized new therapeutic researches of ALL and updated latest progress in clinical trials on bispecific antibodies, antibody-drug conjugates, and new regimens incorporating these novel antibodies. BioMed Central 2019-02-08 /pmc/articles/PMC6368716/ /pubmed/30736842 http://dx.doi.org/10.1186/s13045-019-0703-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Liu, Delong Zhao, Juanjuan Song, Yongping Luo, Xiaofeng Yang, Ting Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
title | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
title_full | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
title_fullStr | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
title_full_unstemmed | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
title_short | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
title_sort | clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368716/ https://www.ncbi.nlm.nih.gov/pubmed/30736842 http://dx.doi.org/10.1186/s13045-019-0703-z |
work_keys_str_mv | AT liudelong clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT zhaojuanjuan clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT songyongping clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT luoxiaofeng clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT yangting clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia |